CUPERTINO, Calif., March 23, 2022 /PRNewswire/ -- DURECT
Corporation (Nasdaq: DRRX) today announced that Dr. James E. Brown, President and CEO, will be
participating in a panel discussion at the Cantor Virtual Rare
Orphan Disease Summit hosted by Kristen
Kluska, Managing Director, Biotechnology Research Analyst of
Cantor Fitzgerald. The title of the panel is "Small but
Mighty: Innovative Strategies in Tackling Some of the Larger Rare
Orphan Disease Markets" and will take place at 1:00 pm ET on Wednesday, March 30,
2022.
If you have interest in participating in the Cantor Virtual Rare
Orphan Disease Summit, please reach out to your Cantor Fitzgerald
representative.
About DURECT Corporation
DURECT is a biopharmaceutical company committed to
transforming the treatment of acute organ injury and chronic liver
diseases by advancing novel and potentially lifesaving therapies
based on its endogenous epigenetic regulator program. Larsucosterol
(also known as DUR-928), DURECT's lead drug candidate, binds to and
inhibits the activity of DNA methyltransferases (DNMTs), epigenetic
enzymes which are elevated and associated with hypermethylation
found in alcohol-associated hepatitis (AH) patients. Larsucosterol
is in clinical development for the potential treatment of AH, for
which FDA has granted a Fast Track Designation; non-alcoholic
steatohepatitis (NASH) is also being explored. In addition,
POSIMIR® (bupivacaine solution) for infiltration use, a non-opioid
analgesic utilizing the innovative SABER® platform technology, is
FDA-approved and has been exclusively licensed to Innocoll
Pharmaceuticals for development and commercialization in
the United States. For more
information about DURECT, please
visit www.durect.com and follow us on
Twitter https://twitter.com/DURECTCorp.
DURECT Forward-Looking Statement
The statements in
this press release regarding clinical development of larsucosterol
(DUR-928) for potential treatment of AH, the potential to develop
larsucosterol for NASH or other indications, the expected
commercial launch of POSIMIR by Innocoll and potential future
payments we may receive from Innocoll are forward-looking
statements involving risks and uncertainties that can cause actual
results to differ materially from those in such forward-looking
statements. Potential risks and uncertainties include, but are not
limited to, the risks that the AHFIRM trial of larsucosterol in AH
takes longer to conduct than anticipated due to COVID-19 or other
factors, the risk that ongoing and future clinical trials of
larsucosterol do not confirm the results from earlier clinical
or pre-clinical trials, or do not demonstrate the safety or
efficacy or the life-saving potential of larsucosterol in a
statistically significant manner, risks that Innocoll may not
commercialize POSIMIR successfully, if at all, and risks related to
our ability to obtain capital to fund operations and expenses.
Further information regarding these and other risks is included in
DURECT's annual report on Form 10-K filed on March 8, 2022 with the Securities and Exchange
Commission under the heading "Risk Factors." The 10-K and
other public filings are available on our website
www.durect.com under the "Investors" tab.
NOTE: POSIMIR® is a trademark of Innocoll Pharmaceuticals, Ltd.
in the U.S. and a trademark of DURECT Corporation outside of the
U.S. SABER® is a trademark of DURECT Corporation. Other
referenced trademarks belong to their respective
owners. Larsucosterol (DUR-928) is an investigational drug
candidate under development and has not been approved for
commercialization by the U.S. Food and Drug
Administration or other health authorities for any
indication.
View original
content:https://www.prnewswire.com/news-releases/durect-corporation-to-present-at-the-2022-cantor-fitzgerald-virtual-rare-orphan-disease-summit-301509210.html
SOURCE DURECT Corporation